PHOSPHOTEC

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PHOSPHOTEC (PHOSPHOTEC).

How it works

Phosphotec (technetium Tc-99m pyrophosphate) is a radiopharmaceutical that accumulates in damaged myocardial tissue, particularly in areas of necrosis or inflammation. It binds to calcium deposits in mitochondria of irreversibly damaged cells, enabling scintigraphic detection of acute myocardial infarction.

What the body does with it

Metabolism	Technetium Tc-99m pyrophosphate does not undergo significant metabolism; it is eliminated via renal excretion as the intact complex.
Excretion	Renal: >90% as unchanged drug. Biliary/fecal: <10%.
Half-life	Terminal elimination half-life: 2.5-3.0 hours. No significant accumulation with repeat dosing.
Protein binding	Not significantly protein bound (<10%).
Volume of Distribution	0.2-0.3 L/kg. Distributes primarily in extracellular fluid.
Bioavailability	Not applicable; administered intravenously (100% bioavailability).
Onset of Action	Intravenous: Immediate (within 1-2 minutes).
Duration of Action	Intravenous: 4-6 hours. Effect diminishes as phosphate redistributes.

Classification & Brands

Dosing & administration

Intravenous bolus injection: 5-10 mCi (185-370 MBq) for imaging; repeat doses as needed per protocol.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min or dialysis, consider reducing dose by 50% due to prolonged clearance.
Liver impairment	No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential altered biodistribution.
Pediatric use	Weight-based dosing: 0.05-0.15 mCi/kg (0.05-0.15 mCi/kg) IV, minimum dose 0.5 mCi, maximum dose 5 mCi.
Geriatric use	No specific dose adjustment; monitor renal function as age-related decline may prolong blood clearance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PHOSPHOTEC (PHOSPHOTEC).

Breastfeeding	Excreted in human milk. Discontinue breastfeeding for at least 24-48 hours after administration. M/P ratio not established.
Teratogenic Risk	FDA Category C. Phosphate-containing radiopharmaceuticals accumulate in fetal bone. Risk of fetal thyroid ablation from free pertechnetate. Avoid in pregnancy unless benefit outweighs risk.
Fetal Monitoring	Monitor CBC, electrolytes, and renal function prior to administration. Ensure adequate hydration. Fetal exposure minimized by using lowest effective dose.

Warnings & precautions

■ FDA Black Box Warning

Not applicable. PHOSPHOTEC does not carry an FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to technetium Tc-99m pyrophosphate or any component of the formulation

Clinical Precautions

Precautions

["Risk of radiation exposure; minimize exposure to patients and healthcare workers","Use with caution in patients with impaired renal function due to altered clearance","Allergic reactions including anaphylaxis have been reported","Pregnancy and lactation: benefit must outweigh risk"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

PHOSPHOTEC

Clinical safety rating: caution

Comprehensive clinical and safety monograph for PHOSPHOTEC (PHOSPHOTEC).

How it works

What the body does with it

Metabolism	Technetium Tc-99m pyrophosphate does not undergo significant metabolism; it is eliminated via renal excretion as the intact complex.
Excretion	Renal: >90% as unchanged drug. Biliary/fecal: <10%.
Half-life	Terminal elimination half-life: 2.5-3.0 hours. No significant accumulation with repeat dosing.
Protein binding	Not significantly protein bound (<10%).
Volume of Distribution	0.2-0.3 L/kg. Distributes primarily in extracellular fluid.
Bioavailability	Not applicable; administered intravenously (100% bioavailability).
Onset of Action	Intravenous: Immediate (within 1-2 minutes).
Duration of Action	Intravenous: 4-6 hours. Effect diminishes as phosphate redistributes.

Classification & Brands

Dosing & administration

Intravenous bolus injection: 5-10 mCi (185-370 MBq) for imaging; repeat doses as needed per protocol.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min or dialysis, consider reducing dose by 50% due to prolonged clearance.
Liver impairment	No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to potential altered biodistribution.
Pediatric use	Weight-based dosing: 0.05-0.15 mCi/kg (0.05-0.15 mCi/kg) IV, minimum dose 0.5 mCi, maximum dose 5 mCi.
Geriatric use	No specific dose adjustment; monitor renal function as age-related decline may prolong blood clearance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for PHOSPHOTEC (PHOSPHOTEC).

Breastfeeding	Excreted in human milk. Discontinue breastfeeding for at least 24-48 hours after administration. M/P ratio not established.
Teratogenic Risk	FDA Category C. Phosphate-containing radiopharmaceuticals accumulate in fetal bone. Risk of fetal thyroid ablation from free pertechnetate. Avoid in pregnancy unless benefit outweighs risk.
Fetal Monitoring	Monitor CBC, electrolytes, and renal function prior to administration. Ensure adequate hydration. Fetal exposure minimized by using lowest effective dose.

Warnings & precautions

■ FDA Black Box Warning

Not applicable. PHOSPHOTEC does not carry an FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to technetium Tc-99m pyrophosphate or any component of the formulation